Repurposing Medications to Lower Dementia Risk

In recent years, the search for effective treatments for dementia has intensified, particularly as this condition continues to affect an increasing number of individuals worldwide. A pivotal study published in February 2025 has highlighted the potential of repurposing existing medications as a strategy to mitigate dementia risk. The review involved a thorough analysis of 14 studies encompassing a staggering 139 million people and delved into various pharmacological agents and their impacts on dementia.

Finding a New Purpose

Despite the growing prevalence of dementia, effective clinical treatments remain elusive. Researchers are exploring innovative pathways, including the repurposing of existing drugs. This strategy leverages medical data that has been routinely collected, presenting an opportunity to investigate the effects of numerous drugs across diverse patient populations.

Interesting findings have emerged, revealing that some medications prescribed for unrelated health conditions may influence dementia risk positively or negatively. For instance, certain diabetes medications have been linked to a reduction in dementia risk.

Driven by Data

The systematic review conducted by the authors categorized studies based on a data-driven approach, which focuses on analyzing large patient datasets for insights rather than testing specific hypotheses. This approach has distinct advantages, including the ability to uncover unrecognized associations that hypothesis-driven studies may overlook. The researchers sifted through data representing patients from the USA, Japan, South Korea, Germany, and Wales, examining over 200 pharmacological subgroups with detailed scrutiny.

Some Drugs Reduce Dementia Risk

While the study's findings revealed inconsistencies among individual drug impacts, some overarching trends were observed across different classes of medications:

Given the role of inflammation in aging and its connection to Alzheimer’s disease, the inclusion of anti-inflammatories in this list is not unexpected. While clinical trials of these agents have yet to yield favorable outcomes, the authors posit that the timing of drug administration may be critical for their efficacy against cognitive decline.

Other Drugs Increase Dementia Risk

Conversely, certain groups of medications have been implicated in increasing dementia risk:

• Antipsychotics: Linked to increased dementia risk; however, this may result in part from reverse causation.
• Drugs for Diabetes: Associated with heightened dementia risk, warranting further investigation into their side effects.

The authors contend that identifying the mechanisms by which these drugs may contribute to dementia is crucial for avoiding their prescription to susceptible individuals.

Conflicting Results

Interestingly, researchers noted conflicting data regarding certain medication classes, such as antihypertensives and antidepressants, with some studies indicating both increased and decreased dementia risk associated with these drugs. This inconsistency may arise from grouping drugs into classes without considering their unique biological actions, which could lead to oversights regarding beneficial effects:

However, the authors believe the extensive scale of data mitigates the potential influence of false negatives in their findings.

Setting Priorities

The findings from this review carry implications for future research prioritization. Targeting specific drugs or combinations of medications could be necessary in developing effective treatments for dementia:

• Single Drug Studies: Investigating the effects of individual medications.
• Combination Therapies: Exploring the synergistic effects of multiple drugs on dementia pathology.

With the complexity of dementia, a multifaceted approach will likely yield the most promising results in terms of treatment efficacy.

Literature

[1] Underwood, B. R., et al. (2025). Data-driven discovery of associations between prescribed drugs and dementia risk: A systematic review. Alzheimer’s & dementia (New York, N. Y.), 11(1), e70037.

[2] Nørgaard, C. H., et al. (2022). Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia: Data from pooled double-blind randomized controlled trials. Alzheimer’s & dementia (New York, N. Y.), 8(1), e12268.

[3] Muzambi, R., et al. (2020). Common Bacterial Infections and Risk of Dementia or Cognitive Decline: A Systematic Review. Journal of Alzheimer’s disease : JAD, 76(4), 1609–1626.

[4] Levine, K. S., et al. (2023). Virus exposure and neurodegenerative disease risk across national biobanks. Neuron, 111(7), 1086–1093.e2.

[5] Ballard, C., et al. (2020). Drug repositioning and repurposing for Alzheimer disease. Nature reviews. Neurology, 16(12), 661–673.

[6] Cummings, J., et al. (2024). Alzheimer’s disease drug development pipeline: 2024. Alzheimer’s & dementia (New York, N. Y.), 10(2), e12465.

[7] Meyer, P. F., et al. (2019). INTREPAD: A randomized trial of naproxen to slow progress of presymptomatic Alzheimer disease. Neurology, 92(18), e2070–e2080.

[8] Siddiqi, F. H., et al. (2019). Felodipine induces autophagy in mouse brains with pharmacokinetics amenable to repurposing. Nature communications, 10(1), 1817.